Opatanol

How to order Opatanol

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Opatanol on Prescriptsy

Opatanol is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Opatanol eye drops contain olopatadine hydrochloride 1 mg/mL, a dual-action antihistamine and mast cell stabiliser used to treat the signs and symptoms of allergic conjunctivitis.

It provides rapid relief from itching, redness, and tearing caused by exposure to allergens such as pollen, dust mites, animal dander, and mould spores.

One drop is instilled into each affected eye twice daily. Opatanol is a prescription-only medicine (POM) in the United Kingdom, manufactured by Novartis.

Allergic conjunctivitis is one of the most common ocular conditions, affecting an estimated 15 to 20 percent of the UK population.

It is broadly divided into seasonal allergic conjunctivitis (SAC), triggered predominantly by tree, grass, and weed pollens during specific seasons, and perennial allergic conjunctivitis (PAC), caused by year-round allergens such as house dust mites, pet dander, and mould.

Both forms are mediated by a type I (IgE-mediated) hypersensitivity reaction in the conjunctival mucosa.

Symptoms include bilateral eye itching (the hallmark symptom), redness, watering, a gritty or burning sensation, and eyelid swelling.

Although allergic conjunctivitis is not sight-threatening, it significantly affects quality of life, work productivity, and daily activities.

This page provides a comprehensive clinical guide to Opatanol, including its mechanism of action, dosage instructions, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about Opatanol

Before reading further, please note these essential safety points.

• Opatanol is for allergic conjunctivitis only. It should not be used for eye infections, contact lens irritation, or other non-allergic eye conditions.
• Remove contact lenses before use and wait at least 15 minutes before reinserting them.
• Discard the bottle 4 weeks after first opening, even if solution remains.
• If you experience eye pain, visual changes, or marked redness, seek prompt medical advice as these may indicate a different condition.

Understanding allergic conjunctivitis

Allergic conjunctivitis occurs when the conjunctiva, the thin transparent membrane covering the white of the eye and the inner surface of the eyelids, reacts to an allergen.

In sensitised individuals, exposure to the allergen triggers mast cells in the conjunctival tissue to release histamine and other inflammatory mediators.

This process occurs through the IgE-mediated pathway: on first exposure, the immune system produces allergen-specific IgE antibodies that bind to receptors on mast cells.

On subsequent exposure, the allergen cross-links these IgE molecules, triggering mast cell degranulation and the release of preformed mediators (primarily histamine) and newly synthesised mediators (prostaglandins, leukotrienes, cytokines).

Histamine is the principal mediator of the immediate allergic response in the eye.

It acts on H1 receptors on conjunctival blood vessels, causing vasodilation (redness), increased vascular permeability (swelling and chemosis), and stimulation of sensory nerve endings (itching).

The early-phase response occurs within minutes of allergen exposure.

A late-phase response, involving recruitment of eosinophils, basophils, and T lymphocytes, may follow 4 to 24 hours later, contributing to prolonged symptoms.

Seasonal allergic conjunctivitis typically peaks during spring and summer when pollen counts are high.

Tree pollens (birch, oak, ash) predominate in March to May, grass pollens in May to July, and weed pollens (nettle, dock) in late summer.

In the UK, the Met Office provides daily pollen forecasts that can help patients plan outdoor activities and time their treatment.

Perennial allergic conjunctivitis persists throughout the year, with house dust mites being the most common trigger.

Symptoms may fluctuate with indoor allergen levels, often worsening in autumn and winter when homes are sealed and heating systems circulate dust.

How Opatanol works

Olopatadine has a dual mechanism of action that distinguishes it from many other topical ophthalmic antiallergy medicines.

First, it is a selective, competitive antagonist at the histamine H1 receptor.

By blocking H1 receptors on conjunctival blood vessels and nerve endings, olopatadine prevents histamine from causing vasodilation, increased permeability, and itching. This provides rapid symptomatic relief.

Second, olopatadine stabilises mast cells by inhibiting calcium influx, preventing the degranulation process and the release of histamine and other mediators.

This prophylactic effect reduces both the immediate and late-phase allergic responses, meaning that regular use can help prevent symptoms as well as treat them.

Olopatadine does not have clinically significant activity at muscarinic, adrenergic, dopaminergic, or serotonergic receptors, which explains its favourable side-effect profile.

Unlike older topical antihistamines such as antazoline, olopatadine does not cause significant stinging on instillation.

Unlike vasoconstrictors such as naphazoline, it does not carry the risk of rebound hyperaemia (rebound redness) with prolonged use.

Clinical evidence for olopatadine eye drops

Olopatadine 0.1% (equivalent to 1 mg/mL) has been extensively studied in randomised controlled trials using the conjunctival allergen challenge (CAC) model and environmental exposure studies.

In CAC studies, olopatadine significantly reduced ocular itching and redness compared with placebo at multiple time points, with onset of effect within minutes and duration of action lasting at least 8 hours.

Head-to-head trials have compared olopatadine with other topical antihistamines and mast cell stabilisers.

A multicentre randomised trial comparing olopatadine 0.1% with sodium cromoglicate 2% found that olopatadine provided superior relief of itching and was preferred by patients.

Comparisons with ketotifen 0.025% showed comparable efficacy in reducing itching, but olopatadine was associated with less stinging on instillation.

A Cochrane review of topical antihistamines and mast cell stabilisers for allergic conjunctivitis concluded that dual-action agents (such as olopatadine and ketotifen) offer the most practical approach to management, combining immediate symptomatic relief with preventive activity in a single formulation.

NICE Clinical Knowledge Summaries (CKS) on allergic conjunctivitis recommend topical antihistamines as first-line treatment for mild to moderate disease, with dual-action agents being a convenient choice.

Opatanol compared with other eye allergy treatments

Several topical treatments are available for allergic conjunctivitis in the UK.

Sodium cromoglicate 2% eye drops (Opticrom, available as a pharmacy medicine) are a mast cell stabiliser that requires four times daily dosing and takes several days to reach full effect.

Antazoline/xylometazoline (Otrivine-Antistin, pharmacy medicine) provides rapid relief but contains a vasoconstrictor that can cause rebound redness with prolonged use.

Ketotifen 0.025% (Zaditen, pharmacy medicine) is a dual-action agent similar to olopatadine, dosed twice daily.

Azelastine 0.05% (Optilast, POM) is a topical antihistamine dosed twice daily with a rapid onset. Epinastine 0.05% (Relestat, POM) is another topical antihistamine option.

Oral antihistamines such as cetirizine, loratadine, and fexofenadine provide systemic allergy relief affecting the nose, skin, and eyes, but their ocular efficacy is generally inferior to topical eye drops for isolated eye symptoms.

Many patients with allergic rhinoconjunctivitis benefit from a combination of an oral antihistamine (for nasal and systemic symptoms) and a topical ocular agent (for eye-specific symptoms).

Intranasal corticosteroid sprays (mometasone, fluticasone) are the most effective treatment for allergic rhinitis and may indirectly improve eye symptoms through the naso-ocular reflex.

Dosage and administration

Instil one drop of Opatanol into each affected eye twice daily, approximately 8 hours apart. A typical schedule would be morning and evening. Wash your hands before use.

Tilt your head back, gently pull down the lower eyelid, and instil one drop into the pocket formed.

Close your eye and press gently on the inner corner near the nose for 1 to 2 minutes to minimise drainage into the nasolacrimal duct, which reduces the chance of a bitter taste in the mouth.

Do not touch the dropper tip to the eye or any surface.

If you wear contact lenses, remove them before instilling the drops and wait at least 15 minutes before reinserting.

If using other eye drops, allow at least 5 minutes between applications.

Discard the bottle 4 weeks after first opening, regardless of how much solution remains, to minimise the risk of contamination.

Store below 25 degrees Celsius and do not freeze.

Side effects of Opatanol

Common side effects

Mild eye discomfort or pain at the instillation site, dry eye sensation, headache, and an unusual or bitter taste in the mouth (dysgeusia) are the most commonly reported side effects.

The taste disturbance occurs because a small amount of the drop drains through the nasolacrimal duct into the throat.

Pressing on the inner corner of the eye after instillation helps reduce this effect.

Uncommon and rare side effects

Transient blurred vision, increased tearing, conjunctival redness, periorbital swelling, photophobia, nasal dryness, and mild drowsiness have been reported uncommonly. Keratitis (corneal inflammation), lid swelling, and dizziness are rare.

Allergic reactions to the active ingredient or preservative are possible but infrequent.

If you experience worsening redness, swelling, or a rash around the eyes, stop using Opatanol and seek medical advice.

Preservative-related effects

Benzalkonium chloride, the preservative in Opatanol, may cause ocular surface irritation in some patients, particularly those with pre-existing dry eye disease or those using multiple preserved eye drops. If persistent irritation develops, discuss preservative-free alternatives with your prescriber or ophthalmologist.

When to seek medical advice

Seek prompt medical advice if you develop eye pain, significant visual changes, severe redness, photophobia, or a discharge that is thick, green, or yellow (suggesting possible infection rather than allergy).

Contact your GP, optometrist, or NHS 111 for guidance. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Opatanol must not be used by patients with known hypersensitivity to olopatadine or any excipient in the formulation, including benzalkonium chloride.

Correct diagnosis

Ensure that your eye symptoms are due to allergy before using Opatanol.

Eye redness and irritation can have many causes, including viral conjunctivitis (often associated with a cold and watery discharge), bacterial conjunctivitis (typically with a thick, purulent discharge), dry eye disease, blepharitis, contact lens problems, and more serious conditions such as uveitis, acute glaucoma, or corneal ulceration.

If you are unsure, consult your GP, optometrist, or pharmacist before starting treatment.

Pregnancy and breastfeeding

There are limited data on the use of olopatadine during pregnancy.

Use Opatanol during pregnancy only if the expected benefit to the mother justifies the potential risk to the foetus, and only on medical advice.

It is not known whether olopatadine passes into breast milk. Use with caution during breastfeeding and discuss the risks and benefits with your prescriber.

Children

Opatanol is approved for children aged 3 years and older. The dose is the same as for adults. It is not recommended for children under 3 years due to insufficient data.

Reducing allergen exposure

Alongside treatment with Opatanol, taking steps to reduce allergen exposure can help control symptoms.

For pollen allergy: check daily pollen forecasts (Met Office), keep windows closed during high pollen periods, shower and change clothes after outdoor exposure, wear wraparound sunglasses outdoors, and avoid drying laundry outside.

For dust mite allergy: use allergen-proof covers on mattresses and pillows, wash bedding at 60 degrees Celsius or above weekly, reduce soft furnishings and carpets in the bedroom, and maintain indoor humidity below 50 percent.

For pet allergy: keep pets out of the bedroom, wash hands after handling animals, and use a HEPA filter air purifier.

How to get Opatanol in the UK

Opatanol is available on NHS prescription from your GP, ophthalmologist, or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Some pharmacies may also sell olopatadine-containing products as pharmacy medicines under different brand names, depending on reclassification status. Consult your pharmacist for current availability.

Sources

• Opatanol 1 mg/ml eye drops, Summary of Product Characteristics (EMC)
• Olopatadine, British National Formulary (BNF)
• NICE CKS: Allergic conjunctivitis
• Conjunctivitis, NHS
• Allergy UK
• MHRA Yellow Card Scheme